Delving into the Latest Updates on Chongqing Kerui Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Infectious Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

PBPs x β-lactamase	1

旨在研究健康受试者单次空腹口服重庆科瑞制药（集团）有限公司研制、生产的枸橼酸铋钾胶囊〔120 mg（按Bi2O3计）〕的药代动力学特征；以TORA LABORATORIES.S.L.持证的枸橼酸铋钾片〔Gastrodenol®，120 mg（以Bi2O3计）〕为参比制剂，证明受试制剂人体铋吸收不高于参比制剂。

[Translation]

The aim was to study the pharmacokinetic characteristics of a single fasting oral administration of bismuth potassium citrate capsules (120 mg (calculated as Bi2O3)) developed and produced by Chongqing Kerui Pharmaceutical (Group) Co., Ltd. to healthy subjects; using bismuth potassium citrate tablets (Gastrodenol®, 120 mg (calculated as Bi2O3)) certified by TORA LABORATORIES.S.L. as the reference preparation, to prove that the human body absorption of bismuth of the test preparation is not higher than that of the reference preparation.

Start Date13 Jan 2025

Sponsor / Collaborator

Chongqing Kerui Pharmaceutical Co. Ltd.

CTR20250044

/ Active, not recruitingNot Applicable

采用单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计，为空腹给药的枸橼酸铋钾颗粒人体药代动力学比较研究

[Translation] A single-center, randomized, open, single-dose, two-formulation, two-period, two-sequence crossover design was used to compare the pharmacokinetics of potassium citrate granules in fasting subjects.

旨在研究健康受试者单次空腹口服重庆科瑞制药（集团）有限公司研制、生产的枸橼酸铋钾颗粒〔120 mg（按Bi2O3计）〕的药代动力学特征；以TORA LABORATORIES.S.L.持证的枸橼酸铋钾片〔Gastrodenol®，120 mg（以Bi2O3计）〕为参比制剂，证明受试制剂人体铋吸收不高于参比制剂。

[Translation]

The aim was to study the pharmacokinetic characteristics of a single fasting oral administration of bismuth potassium citrate granules (120 mg (calculated as Bi2O3)) developed and produced by Chongqing Kerui Pharmaceutical (Group) Co., Ltd. to healthy subjects; using bismuth potassium citrate tablets (Gastrodenol®, 120 mg (calculated as Bi2O3)) certified by TORA LABORATORIES.S.L. as the reference preparation, to prove that the human body absorption of bismuth of the test preparation is not higher than that of the reference preparation.

Start Date13 Jan 2025

Sponsor / Collaborator

Chongqing Kerui Pharmaceutical Co. Ltd.

CTR20210752

/ CompletedNot Applicable

奥美沙坦酯片在中国健康受试者中单剂量、空腹/餐后用药、两制剂、两周期、两序列、随机、开放、自身交叉的平均生物等效性研究

[Translation] A single-dose, fasting/postprandial, two-formulation, two-period, two-sequence, randomized, open-label, self-crossover average bioequivalence study of Olmesartan Medoxomil Tablets in Chinese healthy subjects

主要研究目的：本研究以重庆科瑞制药（集团）有限公司生产的奥美沙坦酯片（规格：20mg）为受试制剂，第一三共制药（上海）有限公司的奥美沙坦酯片（商品名：傲坦®；规格：20mg）为参比制剂，评价受试制剂和参比制剂在空腹/餐后条件下给药时的生物等效性。次要研究目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Main research purpose: This study uses Olmesartan Medoxomil Tablets (specification: 20 mg) produced by Chongqing Kerui Pharmaceutical (Group) Co., Ltd. as the test preparation and Olmesartan Medoxomil Tablets (trade name: Aotan®; specification: 20 mg) produced by Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation when administered under fasting/postprandial conditions. Secondary research purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date11 May 2021

Sponsor / Collaborator

Chongqing Kerui Pharmaceutical Co. Ltd.

100 Clinical Results associated with Chongqing Kerui Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Chongqing Kerui Pharmaceutical Co. Ltd.

Login to view more data

18

Literatures (Medical) associated with Chongqing Kerui Pharmaceutical Co. Ltd.

25 Jun 2024·ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES

The crystal structure of (E)-1-(((2-amino-4,5-dimethylphenyl)iminio)methyl)naphthalen-2-olate, C₁₉H₁₈N₂O

Author: Zou, Hao ; Zhang, Jian-Guo ; Xiong, Hai-Lin

Abstract:

C19H18N2O, orthorhombic, Pna21 (no. 33), a = 21.838(2) Å, b = 13.9663(11) Å, c = 4.9806(4) Å, V = 1519.1(2) Å3, Z = 4, Rgt(F) = 0.0702, wRref(F2) = 0.1948, T = 293 K.

23 Feb 2024·Organic letters

Photoinduced Radical Desulfurative C(sp³)–C(sp²) Coupling via Electron Donor–Acceptor Complexes

Article

Author: Li, Jincan ; Chen, Meijun ; Yue, Xuerong ; Shi, Xin ; Shen, Jiaxuan

Herein, we disclose a radical desulfurative C-C coupling protocol for the synthesis of 4-alkylpyridines. A variety of substituents on both benzyl thiols and 4-cyanopyridines are tolerated. The reaction is carried out under mild and photocatalyst- and transition-metal-free conditions. Preliminary mechanistic studies show that an electron donor-acceptor complex is formed between benzyl thiols and 4-cyanopyridines under alkaline conditions. Then, a variety of 1°, 2°, and 3° C(sp³)-centered radicals was formed by cleavage of the C-S bond, and the 4-alkylpyridines were achieved through a radical-radical coupling with the pyridyl radical anion.

Weiliang Yuansu Yu Jiankang Yanjiu

Analysis and recommendations for determination of heavy metals in Traditional Chinese medicine

Author: Yao, Xiulan ; Wang, Aiping

A review.Anal. and recommendations for determination of heavy metals in Traditional Chinese medicine were introduced.

100 Deals associated with Chongqing Kerui Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Chongqing Kerui Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data